Entries by

TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients

22/02/2022 in /by

Our portfolio company Targed Biopharmaceuticals raised Series A financing of € 39 million to develop improved treatments for thrombotic diseases. The financing was co-led by Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures, and joined by existing investors First, Curie Capital and UHSF.   Congratulations to the whole TargED team! Please […]

Utrecht Health Seed Fund’s first anniversary!

03/09/2021 in /by

Before we knew, we’re celebrating Utrecht Health Seed Fund’s first anniversary! And what a year it has been. We can’t express how proud we are of our exceptional portfolio companies and the talented entrepreneurs and scientists driving these ventures: – TargED Biopharmaceuticals is developing a next generation clot-busting drug with unique properties, focusing on Acute […]

SentryX closes €3.2M seed funding round for the development of next generation pain relief therapeutics

10/06/2021 in /by

We are delighted with the new investment in SentryX, a next generation, innovative pain relief therapy platform, focusing on orthopedic surgical post-procedural pain. Press release: June 9, 2021 – Utrecht, the Netherlands SentryX, a spin-off of the University Medical Center Utrecht (the Netherlands) today announced that it raised €3.2M in seed funding for the development of their […]

TargED Biopharmaceuticals appoints Ludo Haazen, M.D. as Chief Medical Officer

03/06/2021 in , , , /by

TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, today announced the appointment of Ludo Haazen as Chief Medical Officer (CMO). Kristof Vercruysse, CEO of TargED commented: “We are delighted that Ludo is joining our team as CMO. In Ludo, we found the ideal candidate to support the company’s transition from preclinical to […]

NTrans Technologies closes Series A investment to accelerate development of gene editing therapy

28/05/2021 in /by

We’re excited to be investing in NTrans Technologies BV, a gene editing therapy company focusing on Duchenne Muscular Dystrophy, together with Essential Ventures, BOP Capital and Starfish Innovations. May 27, 2021 Utrecht, The Netherlands – NTrans Technologies (NTrans), a leader in gene editing technologies, today announced a Series A investment of 2 million Euros, led […]